Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension
Authors:
- Pedro Mendes-FerreiraPMPedro Mendes-Ferreira
- Carolina Maia-RochaCMCarolina Maia-Rocha
- Rui AdãoRARui Adão
- Diana Santos-RibeiroDSDiana Santos-Ribeiro
- Paulo Castro-ChavesPCPaulo Castro-Chaves
- André Pedro LourençoALAndré Pedro Lourenço
- Gilles W. De KeulenaerGKGilles W. De Keulenaer
- Adelino Ferreira Leite-MoreiraALAdelino Ferreira Leite-Moreira
- Carmen Brás-SilvaCBCarmen Brás-Silva
- 26 October 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 109 (1) , 44-54
Abstract
Pulmonary arterial hypertension (PAH) is a serious disease that affects both the pulmonary vasculature and the right ventricle (RV). Current treatment options are insufficient. The cardiac neuregulin (NRG)-1/ErbB system is deregulated during heart failure, and treatment with recombinant human NRG-1 (rhNRG-1) has been shown to be beneficial in animal models and in patients with left ventricular (LV) dysfunction. This study aimed to evaluate the effects of rhNRG-1 in RV function and pulmonary vasculature in monocrotaline (MCT)-induced PAH and RV hypertrophy (RVH). Male wistar rats (7- to 8-weeks old, n = 78) were injected with MCT (60 mg/kg, s.c.) or saline and treated with rhNRG-1 (40 µg/kg/day) or vehicle for 1 week, starting 2 weeks after MCT administration. Another set of animals was submitted to pulmonary artery banding (PAB) or sham surgery, and followed the same protocol. MCT administration resulted in the development of PAH, pulmonary arterial and RV remodelling, and dysfunction, and increased RV markers of cardiac damage. Treatment with rhNRG-1 attenuated RVH, improved RV function, and decreased RV expression of disease markers. Moreover, rhNRG-1 decreased pulmonary vascular remodelling and attenuated MCT-induced endothelial dysfunction. The anti-remodelling effects of rhNRG-1 were confirmed in the PAB model, where rhNRG-1 treatment was able to attenuate PAB-induced RVH. rhNRG-1 treatment attenuates pulmonary arterial and RV remodelling, and dysfunction in a rat model of MCT-induced PAH and has direct anti-remodelling effects on the pressure-overloaded RV.Keywords
Funding Information
- The Portuguese Foundation for Science and Technology (FCT- PTDC/SAU-FCT/100442/2008, PTDC/DTP-FTO/0130/2012 partially funded by FEDER through COMPETE, SFRH/BD/87714/2012, SFRH/BD/96403/2013)
- ‘Fonds voor Wetenschappelijk Onderzoek’ (G0C5214)
This publication has 44 references indexed in Scilit:
- The striated muscles in pulmonary arterial hypertension: adaptations beyond the right ventricleEuropean Respiratory Journal, 2015
- The Need to Recognize the Pulmonary Circulation and the Right Ventricle as an Integrated Functional Unit: Facts and Hypotheses (2013 Grover Conference series)Pulmonary Circulation, 2015
- Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertensionEuropean Respiratory Journal, 2014
- Early detection of pulmonary arterial hypertensionNature Reviews Cardiology, 2014
- Anti‐Remodeling and Anti‐Fibrotic Effects of the Neuregulin‐1β Glial Growth Factor 2 in a Large Animal Model of Heart FailureJournal of the American Heart Association, 2014
- Therapeutic potential of neuregulin-1 in cardiovascular diseaseDrug Discovery Today, 2013
- Current pathophysiological concepts and management of pulmonary hypertensionInternational Journal of Cardiology, 2012
- Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heartJournal of Cellular Physiology, 2010
- Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart FailureCirculation, 2009
- Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and DiseaseCirculation, 2007